Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis

Internal Medicine

Volumn 41, Issue 6, 2002, Pages 467-473

  Miyata, Masayuki ^a   Sakuma, Fumitaka ^a   Fukaya, Etsuko ^b   Kobayashi, Hiroko ^b   Takeshi, R A I ^b   Saito, Hironobu ^b   Kasukawa, Reiji ^c   Suzuki, Shuzo ^b  

^a Fukushima Red Cross Hospital   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c Ohta General Hospital Foundation   (Japan)

Author keywords

MTX; Pneumonitis; Pulmonary adenocarcinoma; Pulmonary tuberculosis; Type II pneumocyte

Indexed keywords

CARBOHYDRATE ANTIGEN; GOLD SALT; KL 6 ANTIGEN; METHOTREXATE; PREDNISOLONE; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; ANTIGEN; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; GLUCOCORTICOID; GLYCOPROTEIN; METHYLPREDNISOLONE; MUC1 PROTEIN, HUMAN; MUCIN; TUMOR ANTIGEN;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LUNG INJURY; MALE; OUTCOMES RESEARCH; PATIENT MONITORING; PNEUMONIA; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYME LINKED IMMUNOSORBENT ASSAY; INTERSTITIAL LUNG DISEASE; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIGENS; ANTIGENS, NEOPLASM; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; GLYCOPROTEINS; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; MUCINS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0035992795     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.467     Document Type: Article

References (23)

1. Methotrexate pneumonitis in rheumatoid arthritis: Potential risk factors. Four case reports and a review of the literature
2. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis
3. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study
4. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate
5. Interstitial rheumatoid lung disease. A reassessment and review of the literature
6. Pulmonary dysfunction in rheumatoid disease
7. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6
8. Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia
9. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids
10. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases
11. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma
12. Enzyme-linked immunosorbent assay for human pulmonary surfactant protein D
13. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: A multicenter study with literature review
14. Idiopathic Pulmonary Fibrosis
15. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin
16. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis
17. Down-modulation of epidermal growth factor receptor accompanies TNF-induced differentiation of the DiFi human adenocarcinoma cell line toward a goblet-like phenotype
18. Surfactant proteins A and D: Disease markers
19. Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis
20. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts
21. Surfactant proteins A and D bind CD14 by different mechanisms
22. The clinical study on KL-6 and SP-D in sera of patients with various pulmonary diseases
23. Pulmonary function in patients receiving long-term low-dose methotrexate